Venmax Drugs and Pharmaceuticals Limited (BOM:531015)

BOM:531015 Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	44.14	8.07	-	-	-	1.68
Revenue Growth (YoY)	830.42%	-	-	-	-	-64.45%
Cost of Revenue	39.21	7.95	0.1	-	-	2.94
Gross Profit	4.93	0.12	-0.1	-	-	-1.26
Selling, General & Admin	1.75	0.47	0.23	0.3	0.19	0.63
Other Operating Expenses	4.84	10.07	0.73	1.55	1.08	-0.38
Operating Expenses	6.64	10.6	1.02	1.94	1.36	0.35
Operating Income	-1.71	-10.48	-1.12	-1.94	-1.36	-1.62
Other Non Operating Income (Expenses)	10.91	10.52	1.99	4.19	19.83	-
EBT Excluding Unusual Items	9.19	0.05	0.87	2.26	18.47	-1.62
Asset Writedown	-0.19	-0.19	-	-	-	-
Pretax Income	9	-0.14	0.87	2.26	18.47	-1.62
Income Tax Expense	0.28	-0.04	0.22	0	0	0.01
Net Income	8.72	-0.11	0.65	2.26	18.46	-1.62
Net Income to Common	8.72	-0.11	0.65	2.26	18.46	-1.62
Net Income Growth	-	-	-71.41%	-87.78%	-	-
Shares Outstanding (Basic)	6	5	5	5	5	5
Shares Outstanding (Diluted)	6	5	5	5	5	5
Shares Change (YoY)	22.02%	-	-	-	0.00%	-
EPS (Basic)	1.37	-0.02	0.12	0.43	3.52	-0.31
EPS (Diluted)	1.37	-0.02	0.12	0.43	3.52	-0.31
EPS Growth	-	-	-72.09%	-87.78%	-	-
Free Cash Flow	-115.49	-22.9	0.02	-0.03	19.05	2.64
Free Cash Flow Per Share	-18.18	-4.37	0.00	-0.01	3.64	0.50
Gross Margin	11.16%	1.52%	-	-	-	-75.35%
Operating Margin	-3.88%	-129.77%	-	-	-	-96.38%
Profit Margin	19.76%	-1.30%	-	-	-	-96.78%
Free Cash Flow Margin	-261.66%	-283.69%	-	-	-	157.18%
EBITDA	-1.67	-10.41	-1.05	-1.86	-1.27	-1.51
EBITDA Margin	-3.78%	-128.97%	-	-	-	-90.22%
D&A For EBITDA	0.05	0.06	0.07	0.08	0.09	0.1
EBIT	-1.71	-10.48	-1.12	-1.94	-1.36	-1.62
EBIT Margin	-3.88%	-129.77%	-	-	-	-96.38%
Effective Tax Rate	3.12%	-	25.74%	0.04%	0.02%	-
Revenue as Reported	55.05	18.61	1.99	4.19	19.83	3.49
Advertising Expenses	-	0.07	-	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.